Huakang Gene Research Institute (HKGRI)
Our Team
HKGRI is led by President and Director Wei Wei, who has guided the establishment of research platforms, secured patents in both invention and utility models, and overseen the development of the BestSeq™ technology at a world-leading level. Under his leadership, HKGRI collaborated with the National Center for Cardiovascular Diseases (Fuwai Hospital) to advance research on hypertrophic cardiomyopathy (HCM) and other cardiovascular monogenic disorders; with Prof. Jiang Yuwu at Peking University First Hospital on epilepsy diagnostics; and with Prof. Yang Yong at Peking University on dermatological genetics. These achievements have significantly advanced both Chinese medical science and national health.
The research team includes members who have studied or worked at leading institutions in the U.S., Germany, Australia, Japan, and other countries. With extensive international perspective, the team is positioned at the global frontier of gene research, rapidly adapting, innovating, and localizing cutting-edge methods to meet both domestic and global clinical needs. Members bring deep expertise in genomics research, clinical applications, and healthcare management, forming a truly cross-disciplinary team at the forefront of genetic diagnostics and translational medicine.
Research and Publications
HKGRI researchers have long been engaged in pathogenic gene studies, with extensive experience in gene function analysis, diagnostic assay development, and clinical application. Their work has been published in world-class journals including Science, Journal of Clinical Investigation (JCI), Oncogene, and Circulation.
The proprietary BestSeq™ platform technology represents the Institute’s next-generation approach to pathogenic gene detection. Compared with traditional sequencing, BestSeq™ offers higher accuracy, lower cost, and greater efficiency, making it well suited for both clinical and research applications. It has been applied to diagnostic panels for epilepsy, intellectual disability, leukodystrophies, inherited myopathies, and amyotrophic lateral sclerosis (ALS), among others.
Our Clinical Services
Methylated DNA Immunoprecipitation Sequencing (MeDIP-seq)
Whole Genome DNA Bisulfite Sequencing
Epigenetics Research
Small RNA Sequencing
Exome Sequencing
Whole Genome Resequencing
De novo Genome Sequencing Services
Genetic Diagnostic Package for Hereditary Malignant Tumors
Genetic Testing Package for Hereditary Sudden Cardiac Death Disorders
Genetic Testing Package for Hereditary Cardiovascular Diseases
Press and Media
• [CAS News] Breakthrough in low-cost pathogenic gene testing technology
https://www.cas.cn/xw/kjsm/gndt/201205/t20120514_3576888.shtml
• [Peking University Third Hospital] Breakthrough in ALS (motor neuron disease) genetic testing
https://www.lab168.com/news/show-42098.html
• [360zhyx.com] Huakang achieves successful clinical translation of low-cost pathogenic gene testing
https://www.360zhyx.com/home-research-index-rid-29503.shtml